Cargando…
Reasons for accepting or declining to participate in randomized clinical trials for cancer therapy
This paper reports on the reasons why patients agreed to or declined entry into randomized trials of cancer following discussions conducted by clinicians in both District General and University Hospitals. Two hundred and four patients completed a 16-item questionnaire following the consultation, of...
Autores principales: | , |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
2000
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2363224/ https://www.ncbi.nlm.nih.gov/pubmed/10839291 http://dx.doi.org/10.1054/bjoc.2000.1142 |
_version_ | 1782153650593857536 |
---|---|
author | Jenkins, V Fallowfield, L |
author_facet | Jenkins, V Fallowfield, L |
author_sort | Jenkins, V |
collection | PubMed |
description | This paper reports on the reasons why patients agreed to or declined entry into randomized trials of cancer following discussions conducted by clinicians in both District General and University Hospitals. Two hundred and four patients completed a 16-item questionnaire following the consultation, of these 112 (55%) were women with breast cancer. Overall results showed that 147 (72.1%) patients accepted entry to a randomized clinical trial (RCT). The main reasons nominated for participating in a trial were that ‘others will benefit’ (23.1%) and ‘trust in the doctor’ (21.1%). One of the main reasons for declining trial entry was that patients were ‘worried about randomization’ (19.6%). There was a significantly higher acceptance rate for trials providing active treatment in every arm 98 (80.6%) compared with those trials with a no treatment arm 46 (60.5%), χ(2)test P = 0.003. The study outlines a number of factors that appear to influence a patient’s decision to accept or decline entry into an RCT of cancer therapy. An important factor is whether or not the trial offers active treatment in all arms of the study. Communication that promotes trust and confidence in the doctor is also a powerful motivating influence. © 2000 Cancer Research Campaign |
format | Text |
id | pubmed-2363224 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2000 |
publisher | Nature Publishing Group |
record_format | MEDLINE/PubMed |
spelling | pubmed-23632242009-09-10 Reasons for accepting or declining to participate in randomized clinical trials for cancer therapy Jenkins, V Fallowfield, L Br J Cancer Regular Article This paper reports on the reasons why patients agreed to or declined entry into randomized trials of cancer following discussions conducted by clinicians in both District General and University Hospitals. Two hundred and four patients completed a 16-item questionnaire following the consultation, of these 112 (55%) were women with breast cancer. Overall results showed that 147 (72.1%) patients accepted entry to a randomized clinical trial (RCT). The main reasons nominated for participating in a trial were that ‘others will benefit’ (23.1%) and ‘trust in the doctor’ (21.1%). One of the main reasons for declining trial entry was that patients were ‘worried about randomization’ (19.6%). There was a significantly higher acceptance rate for trials providing active treatment in every arm 98 (80.6%) compared with those trials with a no treatment arm 46 (60.5%), χ(2)test P = 0.003. The study outlines a number of factors that appear to influence a patient’s decision to accept or decline entry into an RCT of cancer therapy. An important factor is whether or not the trial offers active treatment in all arms of the study. Communication that promotes trust and confidence in the doctor is also a powerful motivating influence. © 2000 Cancer Research Campaign Nature Publishing Group 2000-06 /pmc/articles/PMC2363224/ /pubmed/10839291 http://dx.doi.org/10.1054/bjoc.2000.1142 Text en Copyright © 2000 Cancer Research Campaign https://creativecommons.org/licenses/by/4.0/This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material.If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit https://creativecommons.org/licenses/by/4.0/. |
spellingShingle | Regular Article Jenkins, V Fallowfield, L Reasons for accepting or declining to participate in randomized clinical trials for cancer therapy |
title | Reasons for accepting or declining to participate in randomized clinical trials for cancer therapy |
title_full | Reasons for accepting or declining to participate in randomized clinical trials for cancer therapy |
title_fullStr | Reasons for accepting or declining to participate in randomized clinical trials for cancer therapy |
title_full_unstemmed | Reasons for accepting or declining to participate in randomized clinical trials for cancer therapy |
title_short | Reasons for accepting or declining to participate in randomized clinical trials for cancer therapy |
title_sort | reasons for accepting or declining to participate in randomized clinical trials for cancer therapy |
topic | Regular Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2363224/ https://www.ncbi.nlm.nih.gov/pubmed/10839291 http://dx.doi.org/10.1054/bjoc.2000.1142 |
work_keys_str_mv | AT jenkinsv reasonsforacceptingordecliningtoparticipateinrandomizedclinicaltrialsforcancertherapy AT fallowfieldl reasonsforacceptingordecliningtoparticipateinrandomizedclinicaltrialsforcancertherapy |